Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride.
Starting from 6-(4'-methoxyphenyl)fulvene (1a), 6-(2',4',6'-trimethoxyphenyl)fulvene (1b), or 6-(3',5'-dimethoxyphenyl)fulvene (1c), [1,2-di(cyclopentadienyl)-1,2-di(4'-methoxyphenyl)-ethanediyl] titanium dichloride (2a), [1,2-di(cyclopentadienyl)-1,2-bis(2',4',6'-trimethoxyphenyl)-ethanediyl] titanium dichloride (2b), and [1,2-di(cyclopentadienyl)-1,2-bis(3',5'-dimethoxyphenyl)-ethanediyl] titanium dichloride (2c) were synthesised. When titanocenes 2a-c were tested against pig kidney carcinoma cells (LLC-PK) inhibitory concentrations (IC50) of 2.8 x 10(-4), 3.6 x 10(-4) and 2.1 x 10(-4) M, respectively, were observed.
Tacke
Matthias
M
Chemistry Department, Centre for Synthesis and Chemical Biology (CSCB), University College Dublin, Belfield, Dublin 4, Ireland. matthias.tacke@ucd.ie
Cuffe
Laurence P
LP
Gallagher
William M
WM
Lou
Ying
Y
Mendoza
Oscar
O
Müller-Bunz
Helge
H
Rehmann
Franz-Josef K
FJ
Sweeney
Nigel
N
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D045744:Cell Line, Tumor; D003517:Cyclopentanes / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D020128:Inhibitory Concentration 50; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008968:Molecular Conformation; D013552:Swine; D014025:Titanium / Q000494:pharmacology* / Q000633:toxicity
D000970:Antineoplastic Agents; D003517:Cyclopentanes; C017332:fulvene; D014025:Titanium